Nektar Therapeutics sold $3.12m in shares-July 23-25
Nektar Therapeutics specializes in the research and development of drugs for the treatment of cancer, autoimmune diseases and chronic pain. Net sales break down by source of income as follows:
- revenues from licensing and collaboration agreements (91.9%);
- product sales (4.6%);
- royalties (3.5%).
At the end of 2018, the Group had a portfolio of 11 products in clinical development (including 4 in phase III, 3 in phase II and 4 in phase I) and a product in pre-clinical development.
Net sales are distributed geographically as follows: the United States (91.4%) and Europe (8.6%).
Number of employees : 509 people.
Howard Robin joined Nektar Therapeutics in January 2007. He has more than 25 years of successful biopharmaceutical experience managing clinical development and commercial operations. Most recently, Mr. Robin served as President and Chief Executive Officer of Sirna Therapeutics, a clinical-stage biotechnology company pioneering RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis C, asthma, respiratory syncytial virus (RSV) and Huntington’s disease. During his tenure at Sirna, Mr. Robin successfully re-launched the company and created significant shareholder value that led to its acquisition by Merck for $1.1 billion.
from July 24th, 2017
Eli Lilly offers $400M-plus deal to bag an early-stage autoimmune drug from Nektar
With little more than preclinical data and some initial dosing cohort insights available for review, Eli Lilly is making a $400 million-plus play to buy into an early-stage autoimmune drug at Nektar $NKTR that the pharma giant believes has megablockbuster potential.